Astra Zeneca said it has begun to enrol 30,000 participants aged over 18 in a late stage study to evaluate its Covid 19 vaccine candidate . 
Participants are being randomised to receive two doses of either of the candidate , AZD1222 , or a saline control , four weeks apart , with twice as many participants receiving the potential vaccine as the saline control , the company said . 
The study is being funded by the US government , the London listed company said . 
